BG107959A - Заместени производни на триазол диамин като киназни инхибитори - Google Patents

Заместени производни на триазол диамин като киназни инхибитори Download PDF

Info

Publication number
BG107959A
BG107959A BG107959A BG10795903A BG107959A BG 107959 A BG107959 A BG 107959A BG 107959 A BG107959 A BG 107959A BG 10795903 A BG10795903 A BG 10795903A BG 107959 A BG107959 A BG 107959A
Authority
BG
Bulgaria
Prior art keywords
alkyl
group
amino
substituted
independently selected
Prior art date
Application number
BG107959A
Other languages
Bulgarian (bg)
English (en)
Inventor
Ronghui Lin
Peter Connolly
Steven Wetter
Shenlin Huang
Stuart Emanual
Robert Guninger
Steven Middleton
Original Assignee
Ortho-Mcneil Pharmaceutical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho-Mcneil Pharmaceutical, Inc. filed Critical Ortho-Mcneil Pharmaceutical, Inc.
Publication of BG107959A publication Critical patent/BG107959A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BG107959A 2000-12-22 2003-07-01 Заместени производни на триазол диамин като киназни инхибитори BG107959A (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25770300P 2000-12-22 2000-12-22

Publications (1)

Publication Number Publication Date
BG107959A true BG107959A (bg) 2004-12-30

Family

ID=22977396

Family Applications (2)

Application Number Title Priority Date Filing Date
BG107959A BG107959A (bg) 2000-12-22 2003-07-01 Заместени производни на триазол диамин като киназни инхибитори
BG107985A BG107985A (bg) 2000-12-22 2003-07-08 Производни на заместени триазолдиамини, използвани като инхибитори на киназа

Family Applications After (1)

Application Number Title Priority Date Filing Date
BG107985A BG107985A (bg) 2000-12-22 2003-07-08 Производни на заместени триазолдиамини, използвани като инхибитори на киназа

Country Status (24)

Country Link
US (2) US6924302B2 (fr)
EP (1) EP1355889B1 (fr)
CN (1) CN100357278C (fr)
AT (1) ATE328874T1 (fr)
BG (2) BG107959A (fr)
BR (1) BR0116792A (fr)
CA (1) CA2432870A1 (fr)
CZ (1) CZ20031941A3 (fr)
DE (1) DE60120494T2 (fr)
DK (1) DK1355889T3 (fr)
ES (1) ES2266313T3 (fr)
HK (1) HK1057373A1 (fr)
HU (1) HUP0303868A3 (fr)
IL (1) IL156584A0 (fr)
MX (1) MXPA03005777A (fr)
NO (1) NO20032848L (fr)
NZ (1) NZ526624A (fr)
PL (1) PL363316A1 (fr)
PT (1) PT1355889E (fr)
RU (1) RU2274639C2 (fr)
SK (1) SK9062003A3 (fr)
WO (1) WO2002057240A1 (fr)
YU (1) YU51803A (fr)
ZA (1) ZA200305619B (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100345593C (zh) * 2002-08-06 2007-10-31 东丽株式会社 用于制备肾脏疾病的治疗或预防药物中的用途
TWI335913B (en) * 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
AU2004251042A1 (en) 2003-05-13 2005-01-06 Depuy Spine, Inc. A method of treating degenerative disc disease
US7344716B2 (en) 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US7429378B2 (en) 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
US7553827B2 (en) 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
US8273347B2 (en) 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
US8361467B2 (en) 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
JP4889489B2 (ja) 2003-08-06 2012-03-07 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼのインヒビターとして有用なアミノトリアゾール化合物
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
DE10356579A1 (de) * 2003-12-04 2005-07-07 Merck Patent Gmbh Aminderivate
WO2005070042A2 (fr) * 2004-01-09 2005-08-04 Smithkline Beecham Corporation Nouveaux composes chimiques
EP1725295B1 (fr) 2004-01-21 2010-09-15 Emory University Compositions et procedes pour utiliser des inhibiteurs de tyrosine kinase afin de traiter une infection pathogenique
AU2005212218A1 (en) * 2004-02-11 2005-08-25 Janssen Pharmaceutica, N.V. Process for the preparation of substituted triazole compounds
JP2008515925A (ja) 2004-10-08 2008-05-15 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ １，２，４−トリアゾリルアミノアリール（ヘテロアリール）スルホンアミド誘導体
KR20070085407A (ko) * 2004-10-21 2007-08-27 버텍스 파마슈티칼스 인코포레이티드 단백질 키나아제의 억제제로서 유용한 트리아졸
DE102004055998A1 (de) 2004-11-19 2006-05-24 Rheinische Friedrich-Wilhelms-Universität Bonn Niedermolekulare Inhibitoren von Guaninnucleotid-Austauschfaktoren der Cytohesin-Familie
US20090036435A1 (en) 2005-01-21 2009-02-05 Astex Therapeutics Limited Pharmaceutical Compounds
US7884119B2 (en) * 2005-09-07 2011-02-08 Rigel Pharmaceuticals, Inc. Triazole derivatives useful as Axl inhibitors
EP2045253A4 (fr) 2006-06-29 2013-01-23 Nissan Chemical Ind Ltd DÉRIVÉ D'ACIDE alpha-AMINÉ ET PRODUIT PHARMACEUTIQUE QUI LE COMPREND EN TANT QUE MATIÈRE ACTIVE
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
EP2073807A1 (fr) 2006-10-12 2009-07-01 Astex Therapeutics Limited Combinaisons pharmaceutiques
DE102006054205A1 (de) * 2006-11-15 2008-05-29 Rheinische Friedrich-Wilhelms Universität Verwendung von Cytohesin-Inhibitoren zur chemischen Induktion von Langlebigkeit
US9422235B2 (en) 2006-12-19 2016-08-23 Pharmos Corporation Sulfonamide derivatives with therapeutic indications
JP2010514810A (ja) * 2006-12-29 2010-05-06 ライジェル ファーマシューティカルズ， インコーポレイテッド Ａｘｌインヒビターとして有用な置換トリアゾール
AU2007342005A1 (en) * 2006-12-29 2008-07-10 Rigel Pharmaceuticals, Inc. N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as Axl inhibitors
ES2406930T3 (es) 2006-12-29 2013-06-10 Rigel Pharmaceuticals, Inc. Triazoles sustituidos con arilo bicíclico y heteroarilo bicíclico útiles como inhibidores de AXL
EP2114955B1 (fr) 2006-12-29 2013-02-13 Rigel Pharmaceuticals, Inc. Triazoles substitués par aryle bicyclique ponté et hétéroaryle bicyclique ponté utilisés comme inhibiteurs d'axl
US7709482B2 (en) 2006-12-29 2010-05-04 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors
JO2784B1 (en) 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
US8440701B2 (en) 2007-10-18 2013-05-14 Janssen Pharmaceutica Nv Trisubstituted 1,2,4 triazoles
WO2009054864A1 (fr) * 2007-10-26 2009-04-30 Rigel Pharmaceuticals, Inc. Triazoles substitués par aryle polycyclique et triazoles substitués par hétéroaryle polycyclique utiles comme inhibiteurs d'axl
US8986696B2 (en) 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
RU2010137300A (ru) 2008-02-22 2012-03-27 Ф. Хоффманн-Ля Рош Аг (Ch) Модуляторы бета-амилоида
NZ587669A (en) 2008-03-19 2011-07-29 Janssen Pharmaceutica Nv Trisubstituted 1, 2, 4 -triazoles as nicotinic acetylcholine receptor modulators
BRPI0912196A2 (pt) 2008-05-09 2015-10-06 Janssen Pharmaceutica Nv pirazóis trissubstituídos como moduladores do receptor de acetilcolina.
CA2730231C (fr) 2008-07-09 2016-10-18 Rigel Pharmaceuticals, Inc. Triazoles a substitution heteroaryle polycycliques utiles en tant qu'inhibiteurs d'axl
JP5613156B2 (ja) 2008-07-09 2014-10-22 ライジェル ファーマシューティカルズ， インコーポレイテッド Ａｘｌ阻害剤として有用な架橋二環ヘテロアリール置換トリアゾール
WO2010040661A1 (fr) 2008-10-09 2010-04-15 F. Hoffmann-La Roche Ag Modulateurs pour l'amyloïde bêta
BRPI0921348A2 (pt) * 2008-11-10 2019-09-24 Hoffmann La Roche moduladores heterocíclicos da gama secretase
AU2010204578B2 (en) * 2009-01-16 2016-05-12 Rigel Pharmaceuticals, Inc. AXL inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
US20140010783A1 (en) * 2012-07-06 2014-01-09 Hoffmann-La Roche Inc. Antiviral compounds
ES2664782T3 (es) * 2012-11-05 2018-04-23 Nantbio, Inc Derivados que contienen sulfonamida cíclica como inhibidores de la ruta de señalización de hedgehog
JP6093456B2 (ja) * 2013-03-05 2017-03-08 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ウイルス性化合物
CA2898107A1 (fr) * 2013-03-06 2014-09-12 F. Hoffmann-La Roche Ag Composes antiviraux
WO2018175670A1 (fr) 2017-03-22 2018-09-27 The Research Foundation For The State University Of New York Inhibiteurs du domaine hémopexine de la métalloprotéinase-9 matricielle et procédés de traitement les utilisant
US20220112166A1 (en) * 2020-10-13 2022-04-14 Yale University Selective JAK2 Pseudokinase Ligands and Methods of Use
KR20240093844A (ko) * 2021-10-26 2024-06-24 바소카데아, 인코포레이티드 Gpr39 단백질의 길항제
CN114292243B (zh) * 2022-01-12 2023-11-21 中山大学 一种三唑类衍生物或其药学上可接受的盐及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2352944A (en) * 1942-07-04 1944-07-04 Gen Electric Triazole derivatives
NL301383A (fr) * 1962-12-06
US4727022A (en) * 1984-03-14 1988-02-23 Syntex (U.S.A.) Inc. Methods for modulating ligand-receptor interactions and their application
US5196351A (en) * 1987-09-30 1993-03-23 Beckman Instruments, Inc. Bidentate conjugate and method of use thereof
US5683867A (en) * 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
JP3672306B2 (ja) * 1991-04-10 2005-07-20 ザ スクリップス リサーチ インスティテュート ファージミドを使用するヘテロ二量体受容体ライブラリー
WO1993005027A1 (fr) * 1991-09-02 1993-03-18 Yamanouchi Pharmaceutical Co., Ltd. Amine tertiaire triazolylee ou un sel de celle-ci
US5543507A (en) * 1992-03-05 1996-08-06 Isis Pharmaceuticals, Inc. Covalently cross-linked oligonucleotides
US5362859A (en) * 1992-07-27 1994-11-08 Sepracor, Inc. High-capacity affinity supports and methods for the preparation and use of same
US5512435A (en) * 1993-02-05 1996-04-30 Renschler; Markus F. Receptor-binding antiproliferative peptides
EP0710654A4 (fr) * 1993-07-23 1996-08-28 Green Cross Corp Derive de triazole et son utilisation pharmaceutique
US5698401A (en) * 1995-11-14 1997-12-16 Abbott Laboratories Use of nuclear magnetic resonance to identify ligands to target biomolecules
KR20010082501A (ko) 1997-10-27 2001-08-30 개리 이. 프라이드만 4-아미노티아졸 유도체, 그 제조방법 및 싸이클린-의존성키나아제의 억제제로서의 이용방법
GB9918180D0 (en) 1999-08-02 1999-10-06 Smithkline Beecham Plc Novel compositions

Also Published As

Publication number Publication date
US20050182116A1 (en) 2005-08-18
EP1355889B1 (fr) 2006-06-07
PT1355889E (pt) 2006-09-29
NO20032848L (no) 2003-08-20
WO2002057240A1 (fr) 2002-07-25
HK1057373A1 (en) 2004-04-02
PL363316A1 (en) 2004-11-15
RU2003118448A (ru) 2005-01-27
CZ20031941A3 (cs) 2004-08-18
HUP0303868A2 (hu) 2004-03-01
RU2274639C2 (ru) 2006-04-20
SK9062003A3 (en) 2004-04-06
BG107985A (bg) 2004-11-30
EP1355889A1 (fr) 2003-10-29
HUP0303868A3 (en) 2008-03-28
YU51803A (sh) 2006-05-25
US7317031B2 (en) 2008-01-08
NZ526624A (en) 2005-07-29
ATE328874T1 (de) 2006-06-15
BR0116792A (pt) 2004-02-17
CN100357278C (zh) 2007-12-26
ZA200305619B (en) 2004-10-21
IL156584A0 (en) 2004-01-04
NO20032848D0 (no) 2003-06-20
ES2266313T3 (es) 2007-03-01
DE60120494T2 (de) 2006-12-21
CN1575284A (zh) 2005-02-02
CA2432870A1 (fr) 2002-07-25
US20040077699A1 (en) 2004-04-22
MXPA03005777A (es) 2005-02-14
US6924302B2 (en) 2005-08-02
DE60120494D1 (de) 2006-07-20
DK1355889T3 (da) 2006-10-09

Similar Documents

Publication Publication Date Title
BG107959A (bg) Заместени производни на триазол диамин като киназни инхибитори
US8273738B2 (en) Imidazole derivatives
TWI437989B (zh) ４－（４－吡啶基）－苯甲醯胺及其作為Ｒｈｏ激酶（ＲＯＣＫ）活性調節劑之用途
EP1382603B1 (fr) Compose azote a anneaux condenses possedant un groupe pyrazolyle et servant de substituant, et composition medicale le comprenant
JP2000514806A (ja) プロテインチロシンキナーゼ阻害剤としての縮合複素環式化合物
WO2001068585A1 (fr) Nouveaux composes amides
SG182187A1 (en) 5-heteroaryl substituted indazoles as kinase inhibitors
CA2812686C (fr) Utilisation de derives de benzazole en tant que ligands des recepteurs h4 de l'histamine
CA2431171A1 (fr) Derives thiazole substitues porteurs de groupes 3-pyridyl, procede d'elaboration et leur utilisation
JPWO2003026661A1 (ja) インスリン分泌促進剤及び新規なピリミジン誘導体
US20090156646A1 (en) Pyridylphenol compound and use thereof
EP2662367B1 (fr) Nouveau dérivé de l'indole ou de l'indazole ou sel de celui-ci
WO2005023782A1 (fr) Compose pyrimidine-4(ch)-one fusionne substitue
EP2522657B1 (fr) Dérivé d'indole
TW200400965A (en) Antiviral compounds
TW202031644A (zh) 苯并咪唑衍生物
AU2002249872B2 (en) Substituted triazole diamine derivatives as kinase inhibitors
EP1712550A2 (fr) Dérivés de triazole diamine substitués comme inhibiteurs de kinases
AU2002249872A1 (en) Substituted triazole diamine derivatives as kinase inhibitors